Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

1000 brain tumor Patients' records reviewed to see what worked

NCT ID NCT07448480

Knowledge-focused Sponsor: Blokhin's Russian Cancer Research Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is not testing a new treatment. Instead, researchers are reviewing medical records from 1000 adults with recurrent malignant gliomas (aggressive brain tumors) to see how well past chemotherapy and targeted therapies worked. The goal is to learn which treatments are linked to longer survival and better outcomes, helping guide future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,000 people

The number who actually took part.

Started

Feb 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of approximately 1000 adult patients (aged ≥ 18 years) with histologically and molecularly confirmed diagnoses of malignant gliomas according to the WHO 2021 classification, including glioblastoma (IDH-wildtype, WHO grade 4), astrocytoma (IDH-mutant, WHO grade 3-4), and pleomorphic xanthoastrocytoma (WHO grade 2-3). All patients had documented disease recurrence or progression with available treatment-related data in medical records sufficient to assess at least one of the study outcome measures (OS, PFS1, PFS2, PFS3, PFS4, or PFS5). Patients were treated at the N.N. Blokhin National Medical Research Center of Oncology between 2005 and 2025. Patients with absent molecular-genetic confirmation according to WHO 2021 classification, insufficient treatment-related data, prior participation in clinical trials with unblinded investigational agents where data cannot be extracted, or synchronous primary malignant neoplasms were excluded from the analysis

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years at the time of initial brain tumor diagnosis; * Histologically confirmed diagnosis of malignant glioma, including: * Glioblastoma, IDH-wildtype (WHO grade 4) * Astrocytoma, IDH-mutant (WHO grade 3-4) * Pleomorphic xanthoastrocytoma (WHO grade 2-3) * Molecularly confirmed diagnosis according to WHO 2021 classification (with available data on IDH1/2, BRAF, 1p/19q, and MGMT status where applicable); * Documented disease recurrence or progression with available treatment-related data in medical records to assess at least one of the study outcome measures Exclusion Criteria: * Age \< 18 years at initial diagnosis; * Absence of molecular-genetic confirmation of the tumor (according to WHO 2021 classification); * Lack of documented disease recurrence or progression, or insufficient treatment-related data in medical records to assess at least one of the study outcome measures; * Prior participation in clinical trials with unblinded investigational agents where data cannot be extracted (except where data are available and verifiable); * Synchronous primary malignant neoplasms.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anaplastic astrocytoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anaplastic astrocytoma astrocytoma (excluding glioblastoma) glioblastoma glioma IDH-wildtype glioblastoma malignant glioma pleomorphic xanthoastrocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anaplastic astrocytoma Glioblastoma Pleomorphic xanthoastrocytoma Recurrent malignant glioma

Contacts and locations

Locations

  • Blokhin's Russian Cancer Research Center

    Moscow, 115478, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.